Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_0DB48862B6C0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
UNIL/CHUV
Titre
Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.
Périodique
The Journal of allergy and clinical immunology
Auteur⸱e⸱s
Kettner A., DellaCorte G., de Blay F., Jacobsen L., Jutel M., Worm M., Charlon V., Simonsen K., Reymond C., Spertini F.
ISSN
1097-6825 (Electronic)
ISSN-L
0091-6749
Statut éditorial
Publié
Date de publication
08/2018
Peer-reviewed
Oui
Volume
142
Numéro
2
Pages
678-680.e7
Langue
anglais
Notes
Publication types: Clinical Trial, Phase II ; Letter ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
A short course of 5 injection AIT with Bet v 1 Contiguous Overlapping Peptides was well tolerated and improved allergic rhinitis during the 2 <sup>nd</sup> pollen season after treatment. Long lasting efficacy was associated with a persistent allergen-specific IgG4 response.

Mots-clé
Administration, Sublingual, Adult, Antigens, Plant/immunology, Antigens, Plant/therapeutic use, Betula/immunology, Desensitization, Immunologic/methods, Europe, Female, Follow-Up Studies, Humans, Hypersensitivity/immunology, Hypersensitivity/therapy, Male, Middle Aged, Peptides/immunology, Peptides/therapeutic use, Pollen/immunology, Quality of Life
OAI-PMH
oai:serval.unil.ch:BIB_0DB48862B6C0
DOI
10.1016/j.jaci.2018.01.052
Pubmed
29678749
Web of science
000440664400036
Création de la notice
26/04/2018 18:46
Dernière modification de la notice
12/09/2019 6:10
Données d'usage